A team of Tel Aviv University researchers claims to have made progress in the path to treating Parkinson’s disease. The team found that a variant of a protein, caused by a genetic mutation, enhances ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...

Nightmares can be caused by a range of conditions from Parkinson's to sleep apnoea - and they can even help diagnose your ...

Understanding how human neurons cope with the energy demands of a large, active brain could open up new avenues for treating ...

Dementia is the umbrella term for all kinds of conditions associated with memory loss of which Alzheimer’s disease is the ...

Diagnosed in 2021, Perry Newman, who is originally from Englee, is fundraising to raise enough money to participate in a ...

Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, today announced a multi-target strategic alliance with GSK to discover and ...

Microscopic analysis by Montana scientists has revealed the first detailed structure of the pathogen that causes chronic ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Researchers have developed a simple model system that can be used to break down fibrils -- the cause of numerous disorders including Alzheimer's and Parkinson's disease -- into their constituent ...

In animal studies, TCE causes selective loss of dopamine-producing nerve cells, a hallmark of Parkinson's disease in humans. Individuals who worked directly with TCE have an elevated risk of ...